A retrospective study of 538 patients with metastatic melanoma treated with anti-PD-1 mAbs from March 2015 to March 2018 in a single quaternary melanoma center revealed positivity of islet autoantibodies in 2 out of 10 patients with irDM, which exclusively concerned GADA [53]. Here, PDCD1 is linked to metastatic melanoma.